Hon ANDREW LITTLE: Pfizer's antiviral drug, which does not yet have a brand name in New Zealand, inhibits replication but in a different way—by preventing the cleavage of certain proteins necessary to create a fully functioning virus. This means you're less likely to get a fully functioning virus. This is similar to molnupiravir, which works by introducing copying errors during replication, which means you're less likely to get a fully functioning virus.